Ha R. Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Mucoadhesive and Self-Assembled Chitosan Oligosaccharide-Glycyrrhizin Nanoparticle for Oral Nanotherapeutic in Inflammatory Bowel Disease.

Mucoadhesive and Self-Assembled Chitosan Oligosaccharide-Glycyrrhizin Nanoparticle for Oral Nanotherapeutic in Inflammatory Bowel Disease.

Journal: ACS nano

Published: August 19, 2025

An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog-mutant cancer.

An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog-mutant cancer.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: July 21, 2025

CD44-targeted nanoparticles for remodeling the tumor microenvironment in a 3D macrophage-embedded ovarian cancer model with stem cell-like features.

CD44-targeted nanoparticles for remodeling the tumor microenvironment in a 3D macrophage-embedded ovarian cancer model with stem cell-like features.

Journal: International journal of pharmaceutics

Published: January 07, 2025

Cell-Penetrating Peptide Like Anti-Programmed Cell Death-Ligand 1 Peptide Conjugate-Based Self-Assembled Nanoparticles for Immunogenic Photodynamic Therapy.

Cell-Penetrating Peptide Like Anti-Programmed Cell Death-Ligand 1 Peptide Conjugate-Based Self-Assembled Nanoparticles for Immunogenic Photodynamic Therapy.

Journal: ACS nano

Published: January 06, 2025

Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment.

Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: May 22, 2024

Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying Peptide-Drug Conjugate.

Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying Peptide-Drug Conjugate.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: April 25, 2024

Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer.

Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: April 09, 2024

Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway.

Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway.

Journal: Biomaterials

Published: January 30, 2024

Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer.

Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer.

Journal: Biomaterials

Published: May 05, 2022

Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC.

Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: February 14, 2022

Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer.

Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: September 27, 2021

Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer.

Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer.

Journal: Biomaterials

Published: February 09, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026